Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information

Rhea-AI Summary

Elite Pharmaceuticals (OTCQB: ELTP) reported financial results for Q1 FY2025 ended June 30, 2024. Highlights include:

- Consolidated revenues of $18.8 million, up 109% year-over-year
- Operating profits of $3.9 million, increased 144% year-over-year
- Net income attributable to common shareholders of $0.6 million

The significant growth in operating profits was primarily due to higher sales of Elite label products. The company will host a conference call on August 15, 2024, at 11:30 AM EDT to discuss the results and provide business updates. Stockholders can submit questions in advance to dianne@elitepharma.com by August 14, 2024, 7:00 PM EDT.

Positive

• Consolidated revenues increased by 109% to $18.8 million
• Operating profits grew by 144% to $3.9 million
• Net income attributable to common shareholders of $0.6 million
• Higher sales achieved by Elite label product line

Negative

• None.

Conference Call Scheduled for Thursday, August 15 at 11:30 AM EDT

Northvale, New Jersey--(Newsfile Corp. - August 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended June 30, 2024, which is the first quarter of the Company's fiscal year ending on March 31, 2025 ("First Quarter").

Consolidated revenues for the three-month period ended June 30, 2024, were $18.8 million, an increase of $9.8 million or approximately 109% as compared to the comparable period of the prior fiscal year. Operating profits were $3.9 million, an increase of $2.3 million or approximately 144%, as compared to the comparable period of the prior fiscal year, and net income attributable to common shareholders was $0.6 million. The increase in operating profits was primarily attributed to higher level of sales achieved by the Elite label product line during the quarter ended June 30, 2024, as compared to the comparable period of the prior year.

Conference Call Information

Elite's management will host a conference call to discuss the First Quarter financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.

Date:	August 15, 2024
Time:	11:30 AM EDT
Dial-in numbers:	1-800-346-7359 (domestic) 1-973-528-0008 (international)
Conference number:	98840
Questions:	dianne@elitepharma.com Financial questions by 7:00 PM EDT on Wednesday, August 14, 2024
Audio Replay:	https://elite.irpass.com/events_presentations

 

The financial statements can be viewed for Elite's First Quarter of Fiscal Year 2025 on Form 10-Q here.

About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA-registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219806

FAQ

What were Elite Pharmaceuticals' (ELTP) Q1 FY2025 revenue and profit figures?

Elite Pharmaceuticals reported consolidated revenues of $18.8 million and operating profits of $3.9 million for Q1 FY2025 ended June 30, 2024.

How much did Elite Pharmaceuticals' (ELTP) revenue grow in Q1 FY2025?

Elite Pharmaceuticals' revenue grew by 109% year-over-year in Q1 FY2025, increasing by $9.8 million compared to the same period in the previous fiscal year.

What was Elite Pharmaceuticals' (ELTP) net income for Q1 FY2025?

Elite Pharmaceuticals reported a net income attributable to common shareholders of $0.6 million for Q1 FY2025 ended June 30, 2024.

When is Elite Pharmaceuticals (ELTP) hosting its Q1 FY2025 earnings call?

Elite Pharmaceuticals is hosting its Q1 FY2025 earnings call on August 15, 2024, at 11:30 AM EDT.